
    
      This was a 24-week open-label randomized study. Forty patients are randomly assigned to
      receive either combination infliximab plus Methotrexate(MTX) (n=20) or Methotrexate(MTX)
      alone (n=20)

      All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with
      persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5
      mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8 Patients in
      combination group receive infliximab 3mg/kg at weeks 0, 2, and 6 and every 8 week thereafter.
      Comprehensive assessment will be made on week 0, 12, 24.
    
  